Source:http://linkedlifedata.com/resource/pubmed/id/15909811
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2005-5-24
|
pubmed:abstractText |
The clinical and endocrine-related effects of 2-week preoperative treatment of endometrial carcinoma patients with a non-steroid inhibitor of letrozole aromatase (femara 2.5 mg/day, n=10) and a steroid inactivator of the enzyme (exemestane 25 mg/day, n=13) were compared. In the first group, pain relief in the lower part of the belly and/or decreased uterine discharge were reported in two cases, as well as a 31% drop in the mean endometrial M-echo (ultrasound) signal. In the exemestane group, two patients revealed moderate uterine discharge decrease matched by a 15.6% decrease in M-signal intensity; no tumor was detected in another patient on completion of the course. Letrozole effect was relatively greater when such parameters as tumor-tissue aromatase level, estrogen concentration in vaginal smear and blood-cholesterol, FSH and LH levels were taken into consideration. However, exemestane therapy involved a relatively sharper drop in the levels of tumor receptors of progesterone and a significantly higher estrogen/progesterone receptor ratio. Hence, no matter how short treatment duration was, both steroid and non-steroid aromatase inhibitors induced effects predominantly associated with lowering estrogen production in endometrial carcinoma patients. This makes a case for further clinical trials of these drugs to deal with the pathology.
|
pubmed:language |
rus
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Androstadienes,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Aromatase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Follicle Stimulating Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Luteinizing Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Nitriles,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Estrogen,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Progesterone,
http://linkedlifedata.com/resource/pubmed/chemical/Triazoles,
http://linkedlifedata.com/resource/pubmed/chemical/exemestane,
http://linkedlifedata.com/resource/pubmed/chemical/letrozole
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0507-3758
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
51
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
71-4
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15909811-Androstadienes,
pubmed-meshheading:15909811-Antineoplastic Agents,
pubmed-meshheading:15909811-Aromatase Inhibitors,
pubmed-meshheading:15909811-Endometrial Neoplasms,
pubmed-meshheading:15909811-Female,
pubmed-meshheading:15909811-Follicle Stimulating Hormone,
pubmed-meshheading:15909811-Humans,
pubmed-meshheading:15909811-Luteinizing Hormone,
pubmed-meshheading:15909811-Nitriles,
pubmed-meshheading:15909811-Receptors, Estrogen,
pubmed-meshheading:15909811-Receptors, Progesterone,
pubmed-meshheading:15909811-Triazoles
|
pubmed:year |
2005
|
pubmed:articleTitle |
[Comparison of letrozole and exemestane used in non-adjuvant therapy of endometrial carcinoma].
|
pubmed:publicationType |
Journal Article,
Comparative Study,
English Abstract
|